CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 703 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01929408
NCT01929408N/ACompleted
CompareCT.gov

Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Fred Hutchinson Cancer Center·observational·Posted Aug 28, 2013·Updated Nov 15, 2019

In Brief

An observational study for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Completed, enrolled 703 participants across 12 sites.

Detailed Summary

The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
CountriesUnited States
CollaboratorsPatient-Centered Outcomes Research Institute, American Cancer Society, Inc.

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 28, 2013
Enrollment StartJul 19, 2013
Primary CompletionDec 4, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 12.8 years ago